IRulya Therapeutics Statistics
NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
39.88-0.06 (-0.15%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRulya Therapeutics by the numbers
IRulya Therapeutics has a market capitalization of $432.4 million based on 10.84M shares outstanding. With trailing EPS of $-162.79, IRulya Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 22.6% above its 50-day average and 46.5% above its 200-day average.
Average daily trading volume is 63.03K shares, or about $2.5 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
IRLA valuation vs. peer median
| Metric | IRLA | Peer median | Difference |
|---|---|---|---|
| Market cap | $432.36M | $438.68M | -1% |
| Avg. volume | 63.03K | 1.33M | -95% |
Peer median across 8 companies: PROK, TECX, TVGN, FENC, CADL, RGNX, SANA, DNA.
Valuation
- Market cap
- $432.36M
- EPS (TTM)
- $-162.79
- Shares outstanding
- 10.84M
Price and trading
- Previous close
- 39.94
- Open
- 39.94
- Day range
- 38.92 – 42.00
- 52-week range
- 15.10 – 910.00
- Beta
- —
- Volume
- 200.56K
- Average volume
- 63.03K
Dividends and events
- Annual dividend
- None
- Next earnings date
- Nov 13, 2026
Additional statistics
- Market Cap
- 432.36M
- Forward Pe
- -8.56
- Eps
- -162.79
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 910.00
- Week52 Low
- 15.10
- Avg Volume
- 63,028.00
- Shares Outstanding
- 10.84M
- Ma50
- 32.52
- Ma200
- 27.23
- Earnings Date
- Nov 13, 2026
- Pct From52w High
- -95.62%
- Pct From52w Low
- 164.11%